“ One of Toshiba’ s core missions is to validate its technology through clinical trials by leaders in the medical field,” explained Satoshi Tsunakawa, President of Toshiba Medical Systems Corporation.
“ CORE320 has shown that it is now possible to perform a comprehensive cardiac functional and morphological analysis in just one, low-dose examination using Aquilion ONE
This technology can reduce the need to perform multiple examinations using different modalities, a true economical advantage and valuable contribution in cardiac healthcare” said Tsunakawa
The Aquilion ONE system, in conjunction with Myocardial Perfusion software available on the Vitrea™fX and Vitrea Enterprise Suite (*1), includes all the features used for CORE 320 data acquisition and analysis, allowing physicians to perform myocardial perfusion imaging in their institution today.
“ Training is another essential part of Toshiba’ s myocardial perfusion solution,” said Tsunakawa